Pharmaceutical Validation Services Market Report 2026

The pharmaceutical validation services market size has grown strongly in recent years. It will grow from $25.43 billion in 2025 to $27.2 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to tightening regulatory compliance norms, expansion of gmp facilities, growth in pharma automation, rise in audit observations, increase in validation documentation needs.

The pharmaceutical validation services market size is expected to see strong growth in the next few years. It will grow to $35.96 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in advanced therapy manufacturing, expansion of continuous manufacturing, higher data integrity enforcement, rising biologics facility builds, demand for lifecycle validation programs. Major trends in the forecast period include digital validation documentation, automated equipment qualification, remote validation audits, integrated process validation suites, data integrity validation platforms.

The expansion of biopharmaceuticals and biosimilars is anticipated to drive the growth of the pharmaceutical validation services market in the future. Biopharmaceuticals and biosimilars are therapeutic products originating from biological sources that necessitate comprehensive testing and validation procedures to ensure their safety and effectiveness. The surge in biopharmaceuticals and biosimilars is fueled by the rising prevalence of chronic and complex diseases, which demand advanced, targeted therapies that conventional small-molecule drugs cannot adequately address. Pharmaceutical validation services guarantee the quality, safety, and efficacy of biopharmaceuticals and biosimilars by systematically confirming that manufacturing processes, equipment, and analytical techniques consistently produce products that comply with strict regulatory standards, thereby enabling dependable scale-up, regulatory approval, and patient confidence in these intricate biologic therapies. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, as of January 2022, the FDA had approved 33 biosimilar products in the US, 21 of which were commercially available. By 2023, FDA-approved biosimilars had grown to 40, with 25 available on the market. Hence, the growth of biopharmaceuticals and biosimilars is propelling the pharmaceutical validation services market forward.

Leading companies operating in the pharmaceutical validation services market are focusing on developing innovative solutions, such as artificial intelligence (AI)‑enabled digital validation platforms, to streamline compliance, reduce manual errors, and accelerate product approval cycles. AI‑enabled digital validation platforms are software systems that use artificial intelligence to automate and integrate validation processes, helping reduce manual errors, ensure regulatory compliance, and speed up documentation and approval cycles. For example, in June 2025, ValGenesis Inc., a US-based digital validation lifecycle management company, launched ValGenesis Smart GxP, an innovative AI-enabled platform designed to unify validation and process development across the product lifecycle, integrating multiple applications such as iVal, iClean, and iOps to automate commissioning, qualification, cleaning validation, and real-time operational data capture, with its AI assistant delivering up to 80% faster document generation and reducing review cycles from weeks to hours while ensuring compliance with global regulatory standards. ValGenesis Smart GxP supports seamless data flow from R&D through commercial manufacturing, enhances visibility and traceability, and accelerates time to market, representing a significant advancement over legacy systems in efficiency, compliance, and digital integration.

In December 2024, QbD Group NV, a Belgium-based life sciences support company, acquired SciencePharma Sp. z o.o. for an undisclosed amount. With this acquisition, QbD Group NV seeks to expand its international presence and strengthen its regulatory and product development capabilities, particularly across Eastern Europe and China. SciencePharma Sp. z o.o. is a Poland-based healthcare consultancy specializing in regulatory affairs, CMC services, and product development support for the pharmaceutical industry.

Major companies operating in the pharmaceutical validation services market are Jacobs Engineering Group Inc., Parexel International Corporation, Sartorius AG, ECS Group Ltd., Computer Aid Inc., ZenQ Ltd., PQE Group S.p.A., SQA Services Ltd., PharmEng Technology Inc., Lachman Consultants Pvt. Ltd., Quality by Design Group Ltd., BioPharma Services Inc., ValSource Inc., Körber AG, PharmOut Consulting Ltd., VMP Consulting Pvt. Ltd., GxP Compliance Ltd., Pharmaligent LLC, Farbridge Pharma Consulting Ltd., and Adris Pharma Validation & Compliance Pvt. Ltd.

Tariffs on validation instruments, sensors, and specialized testing hardware are raising project costs in pharmaceutical validation services. Equipment and facility qualification segments are most affected where imported systems are widely used. Companies in import dependent regions face higher validation budgets. This may delay non critical validation upgrades. At the same time, tariffs are supporting domestic validation tooling suppliers and local technical service ecosystems.

The pharmaceutical validation services market research report is one of a series of new reports that provides pharmaceutical validation services market statistics, including pharmaceutical validation services industry global market size, regional shares, competitors with a pharmaceutical validation services market share, detailed pharmaceutical validation services market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical validation services industry. This pharmaceutical validation services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical validation services are specialized quality assurance activities that confirm and document that pharmaceutical facilities, equipment, processes, and systems consistently operate according to predefined specifications and regulatory requirements. These services help guarantee product quality, patient safety, and regulatory compliance throughout pharmaceutical manufacturing operations.

The primary service types of pharmaceutical validation services include installation qualification, operational qualification, performance qualification, and revalidation. Installation qualification refers to the documented confirmation that equipment or systems are installed in accordance with manufacturer specifications and applicable regulatory standards. These services are offered for product types such as active pharmaceutical ingredient (API) validation, finished pharmaceutical product validation, biologics and biosimilars validation, and medical device validation. They are delivered through onsite validation services and remote validation services, and are utilized by end users including pharmaceutical manufacturers, biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).

The pharmaceutical validation services market includes revenues earned by entities through the process validation, cleaning validation, equipment qualification, facility and utility validation, computer system validation, analytical method validation, data integrity assessment, risk management, and documentation support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.